These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 11745445)

  • 1. Optimizing the use of combined radioimmunotherapy and hypoxic cytotoxin therapy as a function of tumor hypoxia.
    Blumenthal RD; Taylor A; Osorio L; Ochakovskaya R; Raleigh JA; Papadopoulou M; Bloomer WD; Goldenberg DM
    Int J Cancer; 2001 Nov; 94(4):564-71. PubMed ID: 11745445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of equitoxic radioimmunotherapy and chemotherapy in the treatment of human colonic cancer xenografts.
    Blumenthal RD; Sharkey RM; Natale AM; Kashi R; Wong G; Goldenberg DM
    Cancer Res; 1994 Jan; 54(1):142-51. PubMed ID: 8261435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The hypoxic cytotoxin SR 4233 increases the effectiveness of radioimmunotherapy in mice with human non-Hodgkin's lymphoma xenografts.
    Wilder RB; McGann JK; Sutherland WR; Waller EK; Minchinton AI; Goris ML; Knox SJ
    Int J Radiat Oncol Biol Phys; 1994 Jan; 28(1):119-26. PubMed ID: 8270432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Colonic tumor CEA, CSAp and MUC-1 expression following radioimmunotherapy or chemotherapy.
    Modrak DE; Gold DV; Goldenberg DM; Blumenthal RD
    Tumour Biol; 2003; 24(1):32-9. PubMed ID: 12743424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in tumor vascular permeability in response to experimental radioimmunotherapy: a comparative study of 11 xenografts.
    Blumenthal RD; Sharkey RM; Kashi R; Sides K; Stein R; Goldenberg DM
    Tumour Biol; 1997; 18(6):367-77. PubMed ID: 9372870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of combined radioimmunotherapy and chemotherapy for treatment of medullary thyroid cancer.
    Stein R; Juweid M; Zhang CH; Goldenberg DM
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3199s-3206s. PubMed ID: 10541364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic advantage from combining paclitaxel with the hypoxia-selective cytotoxin NLCQ-1 in murine tumor- or human xenograft-bearing mice.
    Papadopoulou MV; Ji M; Ji X; Bloomer WD; Hollingshead MG
    Cancer Chemother Pharmacol; 2002 Dec; 50(6):501-8. PubMed ID: 12451478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypoxic sensitizer and cytotoxin for head and neck cancer.
    Lee DJ; Moini M; Giuliano J; Westra WH
    Ann Acad Med Singap; 1996 May; 25(3):397-404. PubMed ID: 8876907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pretreatment 18F-FAZA PET predicts success of hypoxia-directed radiochemotherapy using tirapazamine.
    Beck R; Röper B; Carlsen JM; Huisman MC; Lebschi JA; Andratschke N; Picchio M; Souvatzoglou M; Machulla HJ; Piert M
    J Nucl Med; 2007 Jun; 48(6):973-80. PubMed ID: 17536108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myelosuppressive changes from single or repeated doses of radioantibody therapy: effect of bone marrow transplantation, cytokines, and hematopoietic suppression.
    Blumenthal RD; Alisauskas R; Lew W; Sharkey RM; Goldenberg DM
    Exp Hematol; 1998 Aug; 26(9):859-68. PubMed ID: 9694507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combining radioimmunotherapy and chemotherapy for treatment of medullary thyroid carcinoma: effectiveness of dacarbazine.
    Stein R; Chen S; Reed L; Richel H; Goldenberg DM
    Cancer; 2002 Jan; 94(1):51-61. PubMed ID: 11815960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The combined use of 131I-labeled antibody and the hypoxic cytotoxin SR 4233 in vitro and in vivo.
    Langmuir VK; Mendonca HL
    Radiat Res; 1992 Dec; 132(3):351-8. PubMed ID: 1475358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 4-[3-(2-Nitro-1-imidazolyl)propylamino]-7-chloroquinoline hydrochloride (NLCQ-1), a novel bioreductive agent as radiosensitizer in vitro and in vivo: comparison with tirapazamine.
    Papadopoulou MV; Ji M; Rao MK; Bloomer WD
    Oncol Res; 2001; 12(8):325-33. PubMed ID: 11589303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The hypoxia-selective cytotoxin NLCQ-1 (NSC 709257) controls metastatic disease when used as an adjuvant to radiotherapy.
    Lunt SJ; Cawthorne C; Ali M; Telfer BA; Babur M; Smigova A; Julyan PJ; Price PM; Stratford IJ; Bloomer WD; Papadopoulou MV; Williams KJ
    Br J Cancer; 2010 Jul; 103(2):201-8. PubMed ID: 20588272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Local hyperthermia and SR 4233 enhance the antitumor effects of radioimmunotherapy in nude mice with human colonic adenocarcinoma xenografts.
    Wilder RB; Langmuir VK; Mendonca HL; Goris ML; Knox SJ
    Cancer Res; 1993 Jul; 53(13):3022-7. PubMed ID: 8319209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypoxia-dependent retinal toxicity of NLCQ-1 (NSC 709257) in BALB/c mice. Comparison with tirapazamine.
    Papadopoulou MV; Ji M; Bloomer WD
    Basic Clin Pharmacol Toxicol; 2011 Jun; 108(6):396-9. PubMed ID: 21205223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy, toxicity and mode of interaction of combination radioimmunotherapy with 5-fluorouracil in colon cancer xenografts.
    Kinuya S; Yokoyama K; Tega H; Hiramatsu T; Konishi S; Watanabe N; Shuke N; Aburano T; Takayama T; Michigishi T; Tonami N
    J Cancer Res Clin Oncol; 1999 Nov; 125(11):630-6. PubMed ID: 10541970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 4-[3-(2-Nitro-1-imidazolyl)propylamino]-7-chloroquinoline hydrochloride (NLCQ-1), a novel bioreductive compound as a hypoxia-selective cytotoxin.
    Papadopoulou MV; Ji M; Rao MK; Bloomer WD
    Oncol Res; 2000; 12(4):185-92. PubMed ID: 11341468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of low pH and hypoxia on the cytotoxic effects of SR4233 and mitomycin C in vitro.
    Skarsgard LD; Vinczan A; Skwarchuk MW; Chaplin DJ
    Int J Radiat Oncol Biol Phys; 1994 May; 29(2):363-7. PubMed ID: 8195034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NLCQ-1 (NSC 709257) in combination with radiation against human glioma U251 xenografts.
    Papadopoulou MV; Bloomer WD; Hollingshead MG
    Anticancer Res; 2005; 25(3B):1865-9. PubMed ID: 16158918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.